BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noris M, Remuzzi G. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol 2008;151:199-209. [PMID: 18070148 DOI: 10.1111/j.1365-2249.2007.03558.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ling M, Murali M. Analysis of the Complement System in the Clinical Immunology Laboratory. Clin Lab Med 2019;39:579-90. [PMID: 31668271 DOI: 10.1016/j.cll.2019.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
2 Chapin J, Eyler S, Smith R, Tsai HM, Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood. 2013;121:4012-4013. [PMID: 23660864 DOI: 10.1182/blood-2013-03-487694] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cantaluppi V, Medica D, Mannari C, Stiaccini G, Figliolini F, Dellepiane S, Quercia AD, Migliori M, Panichi V, Giovannini L, Bruno S, Tetta C, Biancone L, Camussi G. Endothelial progenitor cell-derived extracellular vesicles protect from complement-mediated mesangial injury in experimental anti-Thy1.1 glomerulonephritis. Nephrol Dial Transplant. 2015;30:410-422. [PMID: 25488895 DOI: 10.1093/ndt/gfu364] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
4 Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312-6. [PMID: 19556379 DOI: 10.2215/CJN.01090209] [Cited by in Crossref: 113] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
5 Lesher AM, Song WC. Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010;15:663-75. [PMID: 21040161 DOI: 10.1111/j.1440-1797.2010.01373.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
6 Sánchez-gonzález PD, López-hernández FJ, López-novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Critical Reviews in Toxicology 2011;41:803-21. [DOI: 10.3109/10408444.2011.602662] [Cited by in Crossref: 134] [Cited by in F6Publishing: 136] [Article Influence: 12.2] [Reference Citation Analysis]
7 Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 2009;10:728-33. [PMID: 19503104 DOI: 10.1038/ni.1755] [Cited by in Crossref: 238] [Cited by in F6Publishing: 228] [Article Influence: 18.3] [Reference Citation Analysis]
8 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
9 Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Molecular Immunology 2009;46:1573-94. [DOI: 10.1016/j.molimm.2009.02.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
10 Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010;169:7-13. [PMID: 19707787 DOI: 10.1007/s00431-009-1039-4] [Cited by in Crossref: 86] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
11 Brandstätter H, Schulz P, Polunic I, Kannicht C, Kohla G, Römisch J. Purification and biochemical characterization of functional complement factor H from human plasma fractions: Factor H purification from human plasma fractions. Vox Sanguinis 2012;103:201-12. [DOI: 10.1111/j.1423-0410.2012.01610.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
12 Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A, Schlosser A, Zipfel PF, Reski R, Decker EL. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J 2011;9:373-83. [PMID: 20723134 DOI: 10.1111/j.1467-7652.2010.00552.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
13 Shih AR, Murali MR. Laboratory tests for disorders of complement and complement regulatory proteins. Am J Hematol 2015;90:1180-6. [PMID: 26437749 DOI: 10.1002/ajh.24209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tille A, Lehnert T, Zipfel PF, Figge MT. Quantification of Factor H Mediated Self vs. Non-self Discrimination by Mathematical Modeling. Front Immunol 2020;11:1911. [PMID: 33013842 DOI: 10.3389/fimmu.2020.01911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hebecker M, Alba-Domínguez M, Roumenina LT, Reuter S, Hyvärinen S, Dragon-Durey MA, Jokiranta TS, Sánchez-Corral P, Józsi M. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol 2013;191:912-21. [PMID: 23772024 DOI: 10.4049/jimmunol.1300269] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]